The Swiss Stock Exchange slowed down on Thursday as mid-day approaches. Investors would digest a heap of business results, including the poor Nestlé performance. Outside the Swiss borders, the European Union has estimated the amount of reprisals in the event of failure of the trade agreement with the United States.
Brussels validated retaliatory measures up to 93 billion euros, which would apply on August 7 if commercial negotiations with the United States were to fail, European diplomats said.
A list of American goods, from Bourbon to cars to planes, would be taxed if the Trump administration was to apply customs duties of 30% on European imports from August 1.
This afternoon, “it is above all the meeting of the ECB which should bring volatility to the clues,” added Mr. Plassard. The Euro goalkeeper should maintain her unchanged interest rates, faced with uncertainties in terms of American surcharge.
“The uncertainty in the taxation of American consumers of European products and possible reprisals of the EU are likely to transfer the drop in rates,” said Paul Donovan, chief economist of the UBS global wealth management branch in a comment.
The ECB will not fail to remember that the economic activity of the private sector in the area has experienced its strongest growth in July since August 2024.
On the Swiss Stock Exchange around 10:50 am, the SMI star index was 0.02% at 12,074.39 points. The SLI was nibbled 0.38% at 2010.20 points and the SPI 0.16% to 16,857.22 points. Of the 31 stars values, only six were declining.
ABB had taken the lead (+1.9%), ahead of Sandoz and Straumann (+1.8%each), as well as UBS (+1.6%) still above 30 francs (30.40 francs).
Swatch Group advanced all the way (+1.6%), distanting its Richemont competitor (-0.9%).
The pharmaceutical giant Roche had slowed down its race, sinking by 1.2% after having recorded a net profit up 17% and performed on the American market. His counterpart Novartis was relegated far behind (+0.5%).
The logistician Kühne+Nagel had reversed the trend (+0.1%). The Schindellegi group disappointed expectations, with results penalized by the gloom of world trade and a low dollar.
The third heavy goods vehicle Nestlé weighed on the index (-4.1%). Investors did not taste the decline in revenues or the stagnation of volumes over six months, and seemed to flourish against the diving of 10% of net profit.
On the extended market, the Peptides Bachem champion was unstoppable, flying from 25.2% to 71.60 francs. The group has increased its revenue by 30% and its profit by almost 40% over six months. He drew other pharmacy subcontractors, such as polypeptide (+9.8%) and Siegfried (+4.6%).
Sulzer was solidly in positive terrain (+6.7%) after confirmation of financial forecasts for the whole year.
Galderma was 6.4%, supported by her solid mid-term copy, brought by sales to the United States.
Georg Fischer found negative territories (-1.5%), despite improving its semi-annual profitability.
Calida lost 5.2%, Meier tobler 4.4% and Cembra 9.8% after their mid-term copy. Vontobel sank by 9.6% and Leonteq won 16.10% after seeing their respective profitability back down. (Awp)
